Omnicell’s first quarter was marked by strong execution and operational improvements, leading to results that exceeded Wall Street’s expectations. Management attributed this momentum to rising adoption of its connected devices portfolio, disciplined cost control, and a healthy backlog of orders entering the year. CEO Randall Lipps emphasized that customer demand is increasingly driven by the need for enterprise-wide medication management solutions, particularly as health systems face staffing constraints and push for greater standardization. Lipps highlighted recent wins with large healthcare organizations, such as the U.S. Department of Veterans Affairs, as evidence of Omnicell’s position as a trusted partner for end-to-end medication workflows.
Is now the time to buy OMCL? Find out in our full research report (it’s free for active Edge members).
Omnicell (OMCL) Q1 CY2026 Highlights:
- Revenue: $309.9 million vs analyst estimates of $304.5 million (14.9% year-on-year growth, 1.8% beat)
- Adjusted EPS: $0.55 vs analyst estimates of $0.33 (66% beat)
- Adjusted EBITDA: $44.65 million vs analyst estimates of $31.37 million (14.4% margin, 42.3% beat)
- The company reconfirmed its revenue guidance for the full year of $1.24 billion at the midpoint
- Management raised its full-year Adjusted EPS guidance to $1.90 at the midpoint, a 8.6% increase
- EBITDA guidance for the full year is $160.5 million at the midpoint, above analyst estimates of $153.3 million
- Operating Margin: 5.4%, up from -4.3% in the same quarter last year
- Market Capitalization: $1.98 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Omnicell’s Q1 Earnings Call
- Stanislav Berenshteyn (Wells Fargo): asked about challenges in the retail pharmacy segment and the outlook for EnlivenHealth. EVP Nnamdi Njoku noted ongoing headwinds but pointed to growing demand and Omnicell’s focus on enabling customer cost efficiencies.
- Jessica Tassan (Piper Sandler): questioned the durability of gross margin improvements seen in Q1. CEO Randall Lipps explained that the margin upside was driven by favorable mix and lapping prior-year investments, but cautioned that margins may fluctuate going forward.
- David Larsen (BTIG): asked how Omnicell is adapting to changes in the acute care environment. Njoku responded that health systems are prioritizing system-wide visibility and migration flexibility, which is resonating with customers and driving pipeline growth.
- Allen Lutz (Bank of America): inquired about customer preferences between XTExtend and Titan XT, and the impact on bookings. Lipps confirmed growing interest in Titan XT is shifting customer strategies and deal timing, with some customers pausing upgrades to wait for the new platform.
- William Sutherland (StoneX): asked about the use of leasing and financing options for large deals. Management said offering both capital purchase and leasing models is supporting deal activity and aligning with customer preferences.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be watching (1) the pace and breadth of Titan XT and OmniSphere deployments as initial customers migrate to the new platform, (2) sustained growth in recurring revenue streams from Specialty Pharmacy Services and consumables, and (3) the company’s ability to maintain margin discipline despite tariff-related costs and continued investment in product innovation. Execution on competitive conversions and pipeline expansion will also be important signposts for Omnicell’s progress.
Omnicell currently trades at $43, up from $37.63 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.